TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05292781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOICES
Description: An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: eBook
Description: e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
Study: NCT06106282

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05514496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-019
Description: NX-019 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-019
Description: NX-019 will be administered orally.
Study: NCT06195358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Health (Smartphone) Application
Description: The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Caregiving Materials
Description: The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
Study: NCT04672369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI939
Description: IBI939 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab injection
Study: NCT04764669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Oral hypromellose capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Oral hypromellose capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Oral hypromellose capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Oral hypromellose capsules.
Study: NCT05867030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide is administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib is administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib is administered orally
Study: NCT06013007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICI-guided JINS approach
Description: OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
Study: NCT05869591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG [Eliquis]
Description: Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 MG [Lixiana]
Description: Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
Study: NCT05652673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
Study: NCT06414941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus low-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus low-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus low-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus high-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT05899504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-The-Scope-Clip (OTSC) Stent Fix
Description: A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
Study: NCT06414941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus high-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus high-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT05699070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202211 100mg
Description: DWC202211 for 5 days~Aspirin 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202212 5mg
Description: DWC202212 for 3 days~Rabeprazole 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202211 100mg + DWC202212 5mg
Description: DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg
Study: NCT05979103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Reggae Music and told the stereotype
Description: Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening to Nature Sounds
Description: Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to nature sounds over the 4 weeks. Each day, we will send them a playlist to listen to.
Study: NCT03636958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional antiepileptic treatment
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional antiepileptic treatment
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
Study: NCT06023784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left bundle branch area pacing
Description: Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right ventricular pacing
Description: Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
Study: NCT06423716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
Study: NCT05483244

Intervention type: OTHER
Intervention: discontinuous weaning
Description: Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient.

Intervention type: OTHER
Intervention: continuous weaning
Description: Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient.
Study: NCT05498636

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selinexor combined with Prednisone, Etoposide, and Lenalidomide
Description: Selinexor combined with Prednisone, Etoposide, and Lenalidomide
Study: NCT06351605

Intervention type: DEVICE
Intervention: Valeda Light Delivery System
Description: The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
Study: NCT04707534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT06572956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T/CAR-NK cell injection
Description: One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
Study: NCT06199986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADT Order Check Attestation (Or)
Description: Clinical reminder order check in electronic health record

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Script (Sc)
Description: Provider script added to progress note in electronic health record
Study: NCT05660928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Description: Multidimensional intervention, with mutidisciplinary approach.
Study: NCT05052229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric oxide gas for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air
Description: Medical grade air for inhalation (placebo)
Study: NCT05352022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Unconditional Financial Incentive
Description: No requirements will be placed on how or where funds will be spent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Unconditional Financial Incentive
Description: No requirements will be placed on how or where funds will be spent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Unconditional Financial Incentive
Description: No requirements will be placed on how or where funds will be spent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Food Purchasing Financial Incentive
Description: Incentive for healthy food purchases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Food Purchasing Financial Incentive
Description: Incentive for healthy food purchases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycemic Control Financial Incentive
Description: Incentive for absolute drop in HbA1c

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: mailed education information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: mailed education information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: mailed education information
Study: NCT05493267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vγ2Vδ2 T lymphocyte-based immunotherapy
Description: Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment regimens for MDR-TB
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment regimens for MDR-TB
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Study: NCT05403554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological NI-1801
Description: Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
Study: NCT04936334

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET Scan
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
Study: NCT06540352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Description: The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Description: The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Placebo in tablets
Study: NCT05403554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-1801 in combination with anti-PD1 (Pembrolizumab)
Description: In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NI-1801 in combination with paclitaxel
Description: The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
Study: NCT06179082

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Botox then threads
Description: patients in which Botox injection then threads insertion were used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: threads only
Description: patients in which threads insertion only was used
Study: NCT06009952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryolipolysis and cavitation devices with vegan diet
Description: Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months).